EVO
Evotec SE
EVO lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
EVO Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Under pressure |
EVO's revenue, profitability, cash flow and balance sheet are all currently under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
EVO PE Valuation
EVO has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
EVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect EVO's losses to shrink, with revenue declining.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
EVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.62 | -$0.14 |
| Q1 2026 | -$0.61 | +$0.03 |
| Q4 2025 | -$0.32 | +$0.29 |
| Q3 2025 | -$0.49 | +$0.05 |
| Q2 2025 | -$0.48 | +$0.06 |
| Q1 2025 | -$0.64 | -$0.35 |
| Q4 2024 | -$0.61 | -$0.35 |
| Q3 2024 | -$0.54 | -$0.24 |
EVO lost $0.62 per share over the past year, a bigger loss than the year before.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
EVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $162M | -15% |
| Q1 2026 | $176.9M | -20% |
| Q4 2025 | $278.7M | +13% |
| Q3 2025 | $182.1M | -11% |
| Q2 2025 | $190.2M | -6% |
| Q1 2025 | $222.2M | -4.2% |
| Q4 2024 | $245.8M | +9.9% |
| Q3 2024 | $205.4M | -5.8% |
EVO's revenue is shrinking: $162M last quarter, down 15% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -36% | -19 points |
| Q1 2026 | -35% | -25 points |
| Q4 2025 | 9.6% | +6.5 points |
| Q3 2025 | -27% | -13 points |
| Q2 2025 | -16% | +41 points |
| Q1 2025 | -10% | -1.3 points |
| Q4 2024 | 3.1% | +8.8 points |
| Q3 2024 | -14% | -8.1 points |
EVO's operating margin was −36% last quarter, down 19 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over EVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over EVO on profitability, with a higher operating margin.
EVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$132.8M | -4534% |
| Q1 2026 | -$7.1M | +$52.5M |
| Q4 2025 | $51.7M | -5.2% |
| Q3 2025 | -$98.8M | -724% |
| Q2 2025 | $3M | +$112.7M |
| Q1 2025 | -$59.6M | +$45.8M |
| Q4 2024 | $54.6M | +$102.8M |
| Q3 2024 | $15.8M | +$43.8M |
EVO's free cash flow was −$187M over the past year, against $14M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over EVO on cash generation, producing positive trailing cash flow while its opponent burns cash.
EVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +403K shares |
| 1 year | +0.1% | +334K shares |
| 3 years | +0.5% | +1.7M shares |
| 5 years | +8.2% | +26.9M shares |
| Available history | +19% | +56M shares |
EVO has 356M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $171,079 |
EVO hasn't bought back shares in the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over EVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
EVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 3.4x | Elevated |
| Q2 2024 | 89.3x | High |
| Q1 2024 | 36.0x | High |
| Q4 2023 | 8.8x | High |
| Q3 2023 | 2.6x | Moderate |
| Q2 2023 | 156.6x | High |
| Q2 2022 | -2.7x | Net Cash |
| Q1 2022 | -0.9x | Net Cash |
EVO's net debt is about 3.4 years of its operating earnings (EBITDA), up from 2.6 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over EVO on leverage, with a lower net debt burden relative to earnings.
EVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.1 | Neutral |
| Stochastic | 34.1 | Neutral |
EVO's weekly RSI is 38 (neutral) and its Stochastic is 34 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
EVO PE vs Healthcare Sector
| Metric | EVO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
EVO has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
EVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.56 | 6.4% above |
| 20 week MA | $1.85 | 10% below |
| 50 week MA | $2.57 | 35% below |
| 100 week MA | $3.25 | 49% below |
| 200 week MA | $5.60 | 70% below |
EVO has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
EVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.9 | $17.4 | +35% |
| 2021 | $17.4 | $22.6 | +30% |
| 2022 | $22.6 | $8.06 | -64% |
| 2023 | $8.06 | $11.7 | +46% |
| 2024 | $11.7 | $4.54 | -61% |
| 2025 | $4.54 | $3.11 | -31% |
| 2026 YTD | $3.11 | $1.66 | -47% |
EVO has finished lower in three of the last six years. It's down 47% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over EVO on returns for 2026, with the stronger performance.